ReviewJournal of leukocyte biology2020
ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis.
Review in Journal of leukocyte biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 567 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
567 citing papers in PubMed, 1 synthesis or guideline pooled it, 915 citations in OpenAlex.
- Analysis of Phosphodiesterase-5 (PDE5) Inhibitors in Modulating Inflammatory Markers in Humans: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Effect of L-Citrulline Supplementation on Endothelial Function and Body Composition in Post-COVID-19 Syndrome: A Randomized Clinical Trial.Nutrients · 2026Trial
- A single-blind, randomized, controlled contingency management trial on physiological indices and biomarkers of cardiovascular health in people with cocaine use disorder.Drug and alcohol dependence · 2025Trial
- The role of parasite-derived vesicles in modulating neutrophil responses in emerging human babesiosis.Emerging microbes & infections · 2026Article
- Xuebijing alleviates septic myocardial injury by inhibiting ferroptosis mediated by the ICAM1/TLR signaling pathway.Histology and histopathology · 2026Article
- Human trilayer engineered blood vessel reveals influence of fibroblasts on disease progression in model of Hutchinson-Gilford progeria.Science advances · 2026Article
- Article
- Multi-Omics and Functional Analysis ofToxins · 2026Article
- Bioprinting of miRNA-Induced Spheroids for Vascularized, Heterocellular Bone Regeneration.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2026Article
- Modality matters: Effect of dialysis modality on soluble intercellular adhesion molecule-1 in children on regular hemodialysis.World journal of clinical pediatrics · 2026Article
- Observational
- Integrated Characterization of ceRNA (circRNA/lncRNA/miRNA/mRNA) Regulatory Networks in aAnimals : an open access journal from MDPI · 2026Article
- Article
- Deep molecular profiling of lung neuroendocrine tumours and supra-carcinoids.Molecular cancer · 2026Article
- Genome-Guided Probiotic Mechanisms of Enterococcus hirae SMU2502: Wnt/β-catenin-Driven Intestinal Epithelial Proliferation and Protection Against Salmonella Infection.Probiotics and antimicrobial proteins · 2026Article
- Article
- Plasmin and sterile inflammation jointly drive fatal embryonic liver degeneration in endothelial chromatin remodeler mutant mice.Development (Cambridge, England) · 2026Article
- The Kallikrein-Kinin System: Proteolytic Orchestrators of Tissue Barrier Disruption in Inflammation and Cancer.International journal of molecular sciences · 2026Review
- Article
- Platelet-released growth factors promote pro-angiogenic effects in endothelial cells: a translational perspective on wound healing and regenerative medicine.Stem cell research & therapy · 2026Article
507 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
ICAM-1 is a cell surface glycoprotein and an adhesion receptor that is best known for regulating leukocyte recruitment from circulation to sites of inflammation. However, in addition to vascular endothelial cells, ICAM-1 expression is also robustly induced on epithelial and immune cells in response to inflammatory stimulation. Importantly, ICAM-1 serves as a biosensor to transduce outside-in-signaling via association of its cytoplasmic domain with the actin cytoskeleton following ligand engagement of the extracellular domain. Thus, ICAM-1 has emerged as a master regulator of many essential cellular functions both at the onset and at the resolution of pathologic conditions. Because the role of ICAM-1 in driving inflammatory responses is well recognized, this review will mainly focus on newly emerging roles of ICAM-1 in epithelial injury-resolution responses, as well as immune cell effector function in inflammation and tumorigenesis. ICAM-1 has been of clinical and therapeutic interest for some time now; however, several attempts at inhibiting its function to improve injury resolution have failed. Perhaps, better understanding of its beneficial roles in resolution of inflammation or its emerging function in tumorigenesis will spark new interest in revisiting the clinical value of ICAM-1 as a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.